Literature DB >> 24089901

Validation of mathematical models for the prediction of organs-at-risk dosimetric metrics in high-dose-rate gynecologic interstitial brachytherapy.

Antonio L Damato1, Akila N Viswanathan, Robert A Cormack.   

Abstract

PURPOSE: Given the complicated nature of an interstitial gynecologic brachytherapy treatment plan, the use of a quantitative tool to evaluate the quality of the achieved metrics compared to clinical practice would be advantageous. For this purpose, predictive mathematical models to predict the D2cc of rectum and bladder in interstitial gynecologic brachytherapy are discussed and validated.
METHODS: Previous plans were used to establish the relationship between D2cc and the overlapping volume of the organ at risk with the targeted area (C0) or a 1-cm expansion of the target area (C1). Three mathematical models were evaluated: D2cc = α*C1 + β (LIN); D2cc = α - exp(-β*C0) (EXP); and a mixed approach (MIX), where both C0 and C1 were inputs of the model. The parameters of the models were optimized on a training set of patient data, and the predictive error of each model (predicted D2cc - real D2cc) was calculated on a validation set of patient data. The data of 20 patients were used to perform a K-fold cross validation analysis, with K = 2, 4, 6, 8, 10, and 20.
RESULTS: MIX was associated with the smallest mean prediction error <6.4% for an 18-patient training set; LIN had an error <8.5%; EXP had an error <8.3%. Best case scenario analysis shows that an error ≤ 5% can be achieved for a ten-patient training set with MIX, an error ≤ 7.4% for LIN, and an error ≤ 6.9% for EXP. The error decreases with the increase in training set size, with the most marked decrease observed for MIX.
CONCLUSIONS: The MIX model can predict the D2cc of the organs at risk with an error lower than 5% with a training set of ten patients or greater. The model can be used in the development of quality assurance tools to identify treatment plans with suboptimal sparing of the organs at risk. It can also be used to improve preplanning and in the development of real-time intraoperative planning tools.

Entities:  

Mesh:

Year:  2013        PMID: 24089901      PMCID: PMC7986404          DOI: 10.1118/1.4819946

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  14 in total

1.  Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy.

Authors:  R Pötter; E Van Limbergen; N Gerstner; A Wambersie
Journal:  Radiother Oncol       Date:  2001-01       Impact factor: 6.280

2.  Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.

Authors:  Larissa J Lee; Akila N Viswanathan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-15       Impact factor: 7.038

3.  Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.

Authors:  Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits
Journal:  Radiother Oncol       Date:  2006-01-05       Impact factor: 6.280

4.  Predicting dose-volume histograms for organs-at-risk in IMRT planning.

Authors:  Lindsey M Appenzoller; Jeff M Michalski; Wade L Thorstad; Sasa Mutic; Kevin L Moore
Journal:  Med Phys       Date:  2012-12       Impact factor: 4.071

5.  Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer.

Authors:  Akila N Viswanathan; Robert Cormack; Caroline L Holloway; Cynthia Tanaka; Desmond O'Farrell; Phillip M Devlin; Clare Tempany
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-12       Impact factor: 7.038

6.  3-T MR-guided brachytherapy for gynecologic malignancies.

Authors:  Tina Kapur; Jan Egger; Antonio Damato; Ehud J Schmidt; Akila N Viswanathan
Journal:  Magn Reson Imaging       Date:  2012-08-13       Impact factor: 2.546

7.  CT-guided interstitial implantation of gynecologic malignancies.

Authors:  B Erickson; K Albano; M Gillin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

8.  Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance.

Authors:  Larissa J Lee; Antonio L Damato; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2013-03-13       Impact factor: 2.362

9.  Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society.

Authors:  Akila N Viswanathan; Beth A Erickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

10.  Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.

Authors:  Bashar Al-Qaisieh; Thelma Witteveen; Brendan Carey; Ann Henry; David Bottomley; Jonathan Smith; Kevin Franks; Peter Bownes
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

View more
  1 in total

1.  Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.

Authors:  Ping Zhou; Xiaojie Li; Hao Zhou; Xiao Fu; Bo Liu; Yu Zhang; Sheng Lin; Haowen Pang
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.